$DXCM
DEXCOM INC

2012 Q4 Form 10-Q Financial Statement

#000119312512446973 Filed on November 01, 2012

View on sec.gov

Income Statement

Concept 2012 Q4 2012 Q3 2011 Q3
Revenue $33.30M $23.10M $18.30M
YoY Change 48.66% 26.23% 56.41%
Cost Of Revenue $15.70M $14.70M $10.09M
YoY Change 34.19% 45.69% 23.05%
Gross Profit $17.50M $8.400M $8.200M
YoY Change 63.55% 2.44% 134.29%
Gross Profit Margin 52.55% 36.36% 44.81%
Selling, General & Admin $17.20M $15.40M $13.24M
YoY Change 25.55% 16.31% 27.32%
% of Gross Profit 98.29% 183.33% 161.48%
Research & Development $8.700M $10.30M $8.231M
YoY Change -5.43% 25.14% 32.76%
% of Gross Profit 49.71% 122.62% 100.38%
Depreciation & Amortization $1.800M $2.100M $1.000M
YoY Change 63.64% 110.0% 66.67%
% of Gross Profit 10.29% 25.0% 12.2%
Operating Expenses $25.90M $25.70M $21.50M
YoY Change 13.1% 19.53% 30.3%
Operating Profit -$8.400M -$17.30M -$13.31M
YoY Change -31.15% 30.0% 2.37%
Interest Expense -$200.0K $0.00 $1.000K
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$8.500M -$17.30M -$13.28M
YoY Change -30.89% 30.29% -0.91%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$8.500M -$17.30M -$13.30M
YoY Change -30.33% 30.08% -0.75%
Net Earnings / Revenue -25.53% -74.89% -72.68%
Basic Earnings Per Share
Diluted Earnings Per Share -$122.7K -$250.4K -$197.3K
COMMON SHARES
Basic Shares Outstanding 69.29M shares 69.03M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2012 Q4 2012 Q3 2011 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $48.70M $53.34M $97.30M
YoY Change -40.61% -45.18% 225.42%
Cash & Equivalents $8.100M $4.700M $17.52M
Short-Term Investments $40.60M $48.64M $79.80M
Other Short-Term Assets $2.000M $2.700M $2.500M
YoY Change 11.11% 8.0% -21.88%
Inventory $7.400M $7.141M $6.500M
Prepaid Expenses
Receivables $19.50M $12.40M $9.000M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $77.60M $75.57M $115.2M
YoY Change -25.74% -34.4% 158.88%
LONG-TERM ASSETS
Property, Plant & Equipment $18.90M $18.61M $12.50M
YoY Change 26.0% 48.9% 35.87%
Goodwill $3.200M $3.162M
YoY Change
Intangibles $4.200M $4.313M
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.100M $98.00K $1.000M
YoY Change 1000.0% -90.2% 150.0%
Total Long-Term Assets $28.40M $27.23M $13.60M
YoY Change 77.5% 100.18% 41.67%
TOTAL ASSETS
Total Short-Term Assets $77.60M $75.57M $115.2M
Total Long-Term Assets $28.40M $27.23M $13.60M
Total Assets $106.0M $102.8M $128.8M
YoY Change -12.03% -20.19% 138.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.900M $3.800M $2.700M
YoY Change 39.29% 40.74% -34.15%
Accrued Expenses $14.00M $15.40M $10.40M
YoY Change 35.92% 48.08% 20.93%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $200.0K $0.00
YoY Change -100.0%
Total Short-Term Liabilities $19.50M $20.40M $14.70M
YoY Change 32.65% 38.8% -13.53%
LONG-TERM LIABILITIES
Long-Term Debt $6.800M $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.100M $1.570M $1.000M
YoY Change 110.0% 57.0% -47.37%
Total Long-Term Liabilities $2.100M $1.570M $1.000M
YoY Change 110.0% 57.0% -47.37%
TOTAL LIABILITIES
Total Short-Term Liabilities $19.50M $20.40M $14.70M
Total Long-Term Liabilities $2.100M $1.570M $1.000M
Total Liabilities $29.00M $22.54M $15.70M
YoY Change 81.25% 43.59% -16.93%
SHAREHOLDERS EQUITY
Retained Earnings -$445.6M -$437.1M
YoY Change 13.94%
Common Stock $522.6M $517.4M
YoY Change 5.45%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $77.00M $80.30M $113.1M
YoY Change
Total Liabilities & Shareholders Equity $106.0M $102.8M $128.8M
YoY Change -12.03% -20.19% 138.08%

Cashflow Statement

Concept 2012 Q4 2012 Q3 2011 Q3
OPERATING ACTIVITIES
Net Income -$8.500M -$17.30M -$13.30M
YoY Change -30.33% 30.08% -0.75%
Depreciation, Depletion And Amortization $1.800M $2.100M $1.000M
YoY Change 63.64% 110.0% 66.67%
Cash From Operating Activities -$10.60M -$6.000M -$6.800M
YoY Change -7.83% -11.76% -28.42%
INVESTING ACTIVITIES
Capital Expenditures -$1.400M -$2.900M -$1.500M
YoY Change -60.0% 93.33% -28.57%
Acquisitions
YoY Change
Other Investing Activities $8.000M $6.300M -$9.100M
YoY Change 7900.0% -169.23% -195.79%
Cash From Investing Activities $6.600M $3.400M -$10.60M
YoY Change -288.57% -132.08% -245.21%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 7.300M 1.300M 900.0K
YoY Change 7200.0% 44.44% -43.75%
NET CHANGE
Cash From Operating Activities -10.60M -6.000M -6.800M
Cash From Investing Activities 6.600M 3.400M -10.60M
Cash From Financing Activities 7.300M 1.300M 900.0K
Net Change In Cash 3.300M -1.300M -16.50M
YoY Change -122.15% -92.12% 2650.0%
FREE CASH FLOW
Cash From Operating Activities -$10.60M -$6.000M -$6.800M
Capital Expenditures -$1.400M -$2.900M -$1.500M
Free Cash Flow -$9.200M -$3.100M -$5.300M
YoY Change 15.0% -41.51% -28.38%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2012Q1 us-gaap Business Acquisition Equity Interest Issued Or Issuable Value Assigned
BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned
3900000
CY2012Q1 us-gaap Business Acquisition Contingent Consideration At Fair Value
BusinessAcquisitionContingentConsiderationAtFairValue
2200000
CY2012Q2 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
380000
CY2012Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1695000
CY2011Q2 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
446000
CY2011Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
0
CY2011Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17523000
CY2011Q3 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
384000
CY2011Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
0
CY2012Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2012Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
10520000
CY2012Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1203000
CY2012Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
80253000
CY2012Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8662000
CY2012Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
53400000
CY2012Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2012Q3 us-gaap Business Acquisition Cost Of Acquired Entity Purchase Price
BusinessAcquisitionCostOfAcquiredEntityPurchasePrice
6063000
CY2012Q3 us-gaap Available For Sale Securities Gross Unrealized Losses1
AvailableForSaleSecuritiesGrossUnrealizedLosses1
1000
CY2012Q3 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
47000
CY2012Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-93000
CY2012Q3 us-gaap Liabilities Current
LiabilitiesCurrent
20404000
CY2012Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2688000
CY2012Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1039000
CY2012Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1222000
CY2012Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-437142000
CY2012Q3 us-gaap Assets
Assets
102796000
CY2012Q3 us-gaap Availableforsale Securities Gross Unrealized Gain
AvailableforsaleSecuritiesGrossUnrealizedGain
7000
CY2012Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4744000
CY2012Q3 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
2583000
CY2012Q3 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0
CY2012Q3 us-gaap Inventory Net
InventoryNet
7141000
CY2012Q3 us-gaap Recorded Unconditional Purchase Obligation Due Within One Year
RecordedUnconditionalPurchaseObligationDueWithinOneYear
18700000
CY2012Q3 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
262000
CY2012Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
2387000
CY2012Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
98000
CY2012Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
102796000
CY2012Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
69534000 shares
CY2012Q3 us-gaap Business Acquisition Cost Of Acquired Entity Other Noncash Consideration
BusinessAcquisitionCostOfAcquiredEntityOtherNoncashConsideration
2181000
CY2012Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
48641000
CY2012Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2012Q3 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
3796000
CY2012Q3 us-gaap Goodwill
Goodwill
3162000
CY2012Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
48635000
CY2012Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
2658000
CY2012Q3 us-gaap Liabilities
Liabilities
22543000
CY2012Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1039000
CY2012Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
4313000
CY2012Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
3551000
CY2012Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
2552000
CY2012Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2012Q3 us-gaap Business Acquisition Purchase Price Allocation Amortizable Intangible Assets
BusinessAcquisitionPurchasePriceAllocationAmortizableIntangibleAssets
4600000
CY2012Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2012Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
18613000
CY2012Q3 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
631000
CY2012Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
69250000 shares
CY2012Q3 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
70000
CY2012Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
569000
CY2012Q3 us-gaap Assets Current
AssetsCurrent
75571000
CY2012Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
11207000
CY2012Q3 us-gaap Business Acquisition Contingent Consideration At Fair Value
BusinessAcquisitionContingentConsiderationAtFairValue
2200000
CY2012Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
31900000
CY2012Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3732000
CY2012Q3 dxcm Contingent Consideration Fair Value Disclosure
ContingentConsiderationFairValueDisclosure
1973000
CY2012Q3 dxcm Clinical Trials
ClinicalTrials
556000
CY2012Q3 dxcm Market Value Of Common Stock Issued On Closing
MarketValueOfCommonStockIssuedOnClosing
3882000
CY2012Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
2736000
CY2012Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
517418000
CY2012Q3 us-gaap Business Acquisition Purchase Price Allocation Goodwill Amount
BusinessAcquisitionPurchasePriceAllocationGoodwillAmount
3200000
CY2012Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1570000
CY2012Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1973000
CY2012Q3 dxcm Working Capital
WorkingCapital
55200000
CY2012Q3 dxcm Unrecognized Share Based Compensation Relate To Performance Awards
UnrecognizedShareBasedCompensationRelateToPerformanceAwards
1300000
CY2012Q3 dxcm Accounts Receivable Net Of Allowance And Sales Returns Current
AccountsReceivableNetOfAllowanceAndSalesReturnsCurrent
12357000
CY2012Q3 dxcm Accrued Tax Audit And Legal Fees
AccruedTaxAuditAndLegalFees
969000
CY2012Q3 dxcm Recorded Unconditional Purchase Obligation Due Within One Year Maximum Term
RecordedUnconditionalPurchaseObligationDueWithinOneYearMaximumTerm
1 Y
CY2012Q3 dxcm Acquisition Related Contingent Consideration Short Term
AcquisitionRelatedContingentConsiderationShortTerm
1467000
CY2012Q3 dxcm Sales Return Reserve
SalesReturnReserve
1200000
CY2012Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
69286481 shares
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4889000
CY2010Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
435000
CY2010Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
0
CY2011Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2011Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
6346000
CY2011Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
601000
CY2011Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
104490000
CY2011Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6804000
CY2011Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2011Q4 us-gaap Available For Sale Securities Gross Unrealized Losses1
AvailableForSaleSecuritiesGrossUnrealizedLosses1
14000
CY2011Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-80000
CY2011Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14741000
CY2011Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1781000
CY2011Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
939000
CY2011Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1591000
CY2011Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-391124000
CY2011Q4 us-gaap Assets
Assets
120475000
CY2011Q4 us-gaap Availableforsale Securities Gross Unrealized Gain
AvailableforsaleSecuritiesGrossUnrealizedGain
13000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2553000
CY2011Q4 us-gaap Valuation Allowance Amount
ValuationAllowanceAmount
134700000
CY2011Q4 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0
CY2011Q4 us-gaap Inventory Net
InventoryNet
8171000
CY2011Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
306000
CY2011Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
2993000
CY2011Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
107000
CY2011Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
120475000
CY2011Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
67833000 shares
CY2011Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
79358000
CY2011Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2011Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
2807000
CY2011Q4 us-gaap Goodwill
Goodwill
0
CY2011Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
79359000
CY2011Q4 us-gaap Liabilities
Liabilities
15985000
CY2011Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
939000
CY2011Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
0
CY2011Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
4577000
CY2011Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2011Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2011Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
15019000
CY2011Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2011Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
67549000 shares
CY2011Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
68000
CY2011Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
281000
CY2011Q4 us-gaap Assets Current
AssetsCurrent
104410000
CY2011Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2643000
CY2011Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2011Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
495626000
CY2011Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
963000
CY2011Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
0
CY2011Q4 dxcm Clinical Trials
ClinicalTrials
161000
CY2011Q4 dxcm Accounts Receivable Net Of Allowance And Sales Returns Current
AccountsReceivableNetOfAllowanceAndSalesReturnsCurrent
12547000
CY2011Q4 dxcm Accrued Tax Audit And Legal Fees
AccruedTaxAuditAndLegalFees
735000
CY2011Q4 dxcm Acquisition Related Contingent Consideration Short Term
AcquisitionRelatedContingentConsiderationShortTerm
0
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2696000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.50
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
78044000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-42925000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21515000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1787000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2332000
us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
0
us-gaap Share Based Compensation
ShareBasedCompensation
9933000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
12634000
us-gaap Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
-57000
us-gaap Interest And Other Income
InterestAndOtherIncome
82000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
2000000
us-gaap Operating Income Loss
OperatingIncomeLoss
-32567000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1657000
us-gaap Cost Of Goods Sold
CostOfGoodsSold
25933000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-610000
us-gaap Net Income Loss
NetIncomeLoss
-32495000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18556000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
1231000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
74137000
us-gaap Gross Profit
GrossProfit
25151000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-6000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-32523000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-518000
us-gaap Cost Of Revenue
CostOfRevenue
28694000
dxcm Weighted Average Number Of Outstanding Shares Basic And Diluted
WeightedAverageNumberOfOutstandingSharesBasicAndDiluted
64910000 shares
dxcm Development And Other Cost Of Sales
DevelopmentAndOtherCostOfSales
2761000
dxcm Development Grant And Other Revenue
DevelopmentGrantAndOtherRevenue
8871000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
74662000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-22000
us-gaap Operating Expenses
OperatingExpenses
57718000
us-gaap Revenues
Revenues
53845000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
36203000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-22000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
695000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4457000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
0
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
44974000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
39576000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9900000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-32495000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9748000 shares
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
0
us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
525000
us-gaap Interest Expense
InterestExpense
10000
us-gaap Other Significant Noncash Transaction Value Of Consideration Given1
OtherSignificantNoncashTransactionValueOfConsiderationGiven1
0
dxcm Fair Value Of Contingent Consideration
FairValueOfContingentConsideration
0
dxcm Increase Decrease In Restricted Cash Investing And Financing Activities
IncreaseDecreaseInRestrictedCashInvestingAndFinancingActivities
775000
dxcm Standard Product Warranty Accrual Charges To Costs And Expenses
StandardProductWarrantyAccrualChargesToCostsAndExpenses
1375000
dxcm Standard Product Warranty Accrual Costs Incurred
StandardProductWarrantyAccrualCostsIncurred
1426000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2012
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2012-09-30
dei Entity Central Index Key
EntityCentralIndexKey
0001093557
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Trading Symbol
TradingSymbol
DXCM
dei Entity Registrant Name
EntityRegistrantName
DEXCOM INC
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
1316000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4849000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.67
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
56282000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
21847000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30795000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-81000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-190000
us-gaap Share Based Compensation
ShareBasedCompensation
13858000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2191000
us-gaap Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
-1000
us-gaap Interest And Other Income
InterestAndOtherIncome
65000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1700000
us-gaap Operating Income Loss
OperatingIncomeLoss
-47368000
us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Organization and Business</i></b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">DexCom, Inc. is a medical device company focused on the design, development and commercialization of continuous glucose monitoring (&#x201C;CGM&#x201D;) systems for ambulatory use by people with diabetes and by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients. Unless the context requires otherwise, the terms &#x201C;we,&#x201D; &#x201C;us,&#x201D; &#x201C;our,&#x201D; the &#x201C;company,&#x201D; or &#x201C;DexCom&#x201D; refer to DexCom, Inc. and its subsidiaries.</font></p> </div>
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1030000
us-gaap Cost Of Goods Sold
CostOfGoodsSold
33867000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-664000
us-gaap Net Income Loss
NetIncomeLoss
-46018000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
1858000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2906000
us-gaap Gross Profit
GrossProfit
29032000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
6000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-46031000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
2181000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
782000
us-gaap Operating Expenses
OperatingExpenses
76400000
us-gaap Revenues
Revenues
66634000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
45605000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1287000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-19000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2366000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8096000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
940000
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
61223000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
86225000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13900000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-47305000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10514000 shares
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
1148000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Use of Estimates</i></b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The preparation of consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from these estimates. Significant estimates include excess or obsolete inventories, warranty accruals, employee bonus, clinical study expenses, allowances for returned product, allowance for bad debt, deferral period for recognizing revenue on future performance obligations, accounting for the SweetSpot acquisition, and share-based compensation expense. Excess and obsolete inventories are estimated by identifying the amount of on hand and on order materials compared to expected future sales, taking into account clinical trial and development usage along with new product introductions. Employee bonus estimates are based, in part, on the 2012 bonus plan&#x2019;s authorized target bonus amounts to be awarded from the bonus pool based on the weighted average achievement of certain objectives. Clinical trial expenses are accrued based on estimates of progress under related contracts and include initial set up costs as well as ongoing monitoring over multiple sites in the U.S. and abroad. An allowance for refunds for returned products is determined by analyzing the timing and amounts of past refund activity and considering the impact of newly introduced products.</font></p> </div>
us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
0
us-gaap Interest Expense
InterestExpense
2000
us-gaap Other Significant Noncash Transaction Value Of Consideration Given1
OtherSignificantNoncashTransactionValueOfConsiderationGiven1
6063000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2906000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-19000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22543000
us-gaap Acquisition Costs
AcquisitionCosts
300000
us-gaap Cost Of Revenue
CostOfRevenue
37602000
dxcm Weighted Average Number Of Outstanding Shares Basic And Diluted
WeightedAverageNumberOfOutstandingSharesBasicAndDiluted
68494000 shares
dxcm Option To Renew Lease
OptionToRenewLease
5 Y
dxcm Term Of Lease
TermOfLease
3 Y
dxcm Business Acquisition Contingent Consideration Amounts Payable
BusinessAcquisitionContingentConsiderationAmountsPayable
1100000
dxcm Development And Other Cost Of Sales
DevelopmentAndOtherCostOfSales
3735000
dxcm Development Grant And Other Revenue
DevelopmentGrantAndOtherRevenue
5411000
dxcm Fair Value Of Contingent Consideration
FairValueOfContingentConsideration
940000
dxcm Increase Decrease In Restricted Cash Investing And Financing Activities
IncreaseDecreaseInRestrictedCashInvestingAndFinancingActivities
-100000
dxcm Standard Product Warranty Accrual Charges To Costs And Expenses
StandardProductWarrantyAccrualChargesToCostsAndExpenses
1368000
dxcm Standard Product Warranty Accrual Costs Incurred
StandardProductWarrantyAccrualCostsIncurred
1412000
dxcm Maximum Percentage Of Ownership To Retain Tax Credit Carryforwards
MaximumPercentageOfOwnershipToRetainTaxCreditCarryforwards
0.50 pure
dxcm Potential Rental Rate Adjustment Maximum
PotentialRentalRateAdjustmentMaximum
0.040 pure
dxcm Potential Rental Rate Adjustment Minimum
PotentialRentalRateAdjustmentMinimum
0.025 pure
dxcm Business Acquisition Contingent Consideration Settlement Shares Issued
BusinessAcquisitionContingentConsiderationSettlementSharesIssued
89296 shares
dxcm Business Acquisition Contingent Consideration Settlement
BusinessAcquisitionContingentConsiderationSettlement
1100000
dxcm Sales Return Coverage Period
SalesReturnCoveragePeriod
30 D
CY2011Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.20
CY2011Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8231000
CY2011Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
31000
CY2011Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
600000
CY2011Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13308000
CY2011Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
9230000
CY2011Q3 us-gaap Net Income Loss
NetIncomeLoss
-13278000
CY2011Q3 us-gaap Gross Profit
GrossProfit
8164000
CY2011Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-12000
CY2011Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13271000
CY2011Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
0
CY2011Q3 us-gaap Operating Expenses
OperatingExpenses
21472000
CY2011Q3 us-gaap Revenues
Revenues
18254000
CY2011Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
13241000
CY2011Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2011Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
0
CY2011Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
16656000
CY2011Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3700000
CY2011Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13278000
CY2011Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9748000 shares
CY2011Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
0
CY2011Q3 us-gaap Interest Expense
InterestExpense
1000
CY2011Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
19000
CY2011Q3 us-gaap Cost Of Revenue
CostOfRevenue
10090000
CY2011Q3 dxcm Weighted Average Number Of Outstanding Shares Basic And Diluted
WeightedAverageNumberOfOutstandingSharesBasicAndDiluted
67397000 shares
CY2011Q3 dxcm Development And Other Cost Of Sales
DevelopmentAndOtherCostOfSales
860000
CY2011Q3 dxcm Development Grant And Other Revenue
DevelopmentGrantAndOtherRevenue
1598000
CY2011Q3 dxcm Standard Product Warranty Accrual Charges To Costs And Expenses
StandardProductWarrantyAccrualChargesToCostsAndExpenses
392000
CY2012Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
17000
CY2012Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
600000
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-17322000
CY2012Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
13391000
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
-17263000
CY2011Q3 dxcm Standard Product Warranty Accrual Costs Incurred
StandardProductWarrantyAccrualCostsIncurred
454000
CY2012Q3 us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
600000
CY2012Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.25
CY2012Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10582000
CY2012Q3 us-gaap Gross Profit
GrossProfit
8402000
CY2012Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
14000
CY2012Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17268000
CY2012Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
0
CY2012Q3 us-gaap Operating Expenses
OperatingExpenses
25724000
CY2012Q3 us-gaap Revenues
Revenues
23089000
CY2012Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
15142000
CY2012Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-43000
CY2012Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
278000
CY2012Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
21081000
CY2012Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4900000
CY2012Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17306000
CY2012Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10514000 shares
CY2012Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
0
CY2012Q3 us-gaap Interest Expense
InterestExpense
1000
CY2012Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-19000
CY2012Q3 us-gaap Cost Of Revenue
CostOfRevenue
14687000
CY2012Q3 dxcm Weighted Average Number Of Outstanding Shares Basic And Diluted
WeightedAverageNumberOfOutstandingSharesBasicAndDiluted
69052000 shares
CY2012Q3 dxcm Development And Other Cost Of Sales
DevelopmentAndOtherCostOfSales
1296000
CY2012Q3 dxcm Development Grant And Other Revenue
DevelopmentGrantAndOtherRevenue
2008000
CY2012Q3 dxcm Standard Product Warranty Accrual Charges To Costs And Expenses
StandardProductWarrantyAccrualChargesToCostsAndExpenses
348000
CY2012Q3 dxcm Standard Product Warranty Accrual Costs Incurred
StandardProductWarrantyAccrualCostsIncurred
466000
CY2012Q3 dxcm Inventory Charges To Costs And Expenses
InventoryChargesToCostsAndExpenses
2500000

Files In Submission

Name View Source Status
0001193125-12-446973-index-headers.html Edgar Link pending
0001193125-12-446973-index.html Edgar Link pending
0001193125-12-446973.txt Edgar Link pending
0001193125-12-446973-xbrl.zip Edgar Link pending
d409818d10q.htm Edgar Link pending
d409818dex3101.htm Edgar Link pending
d409818dex3102.htm Edgar Link pending
d409818dex3201.htm Edgar Link pending
d409818dex3202.htm Edgar Link pending
dxcm-20120930.xml Edgar Link completed
dxcm-20120930.xsd Edgar Link pending
dxcm-20120930_cal.xml Edgar Link unprocessable
dxcm-20120930_def.xml Edgar Link unprocessable
dxcm-20120930_lab.xml Edgar Link unprocessable
dxcm-20120930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending